During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in ...

Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.

财联社11月15日讯（记者 卢阿峰）近日，国产双抗的接连出海似乎“复刻”了去年底MNC们“扫货”ADC的行情，成为当前生物医药行业BD交易当之无愧的主角。

就在前两天， 默沙东 ...

11月15日，截至港股收盘，恒生指数下跌0.05%，报19426.34点。康方生物（09926.HK）收报68.75港元/股，上涨1.03%，成交量496.47万股，成交额3.4亿港元，振幅4.92%。

11月14日晚间， 默沙东 宣布获得礼新医药LM-299的全球开发、生产和商业化独家许可，以扩充自己的肿瘤管线。由此，礼新医药将获得5.88亿美元的首付款，以及最高27亿美元的里程碑付款，即交易总价为32.88亿美元。该交易预计将于2024年年内完成 ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...

BURLINGAME, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update ...

Completed Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track to submit a BLA ...

Botensilimab is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend ...

2024年新版国家医保目录预计于本月底公布灵魂砍价月底“开箱”你最期待哪个“救命药”降价图新华社羊城晚报记者陈泽云以价换量、灵魂砍价，谈判桌上见真章！据国家医保局近日消息，2024年国家医保药品目录调整现场谈判已于10月30日顺利结束。